Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug 6;15(8):13615-23.
doi: 10.3390/ijms150813615.

Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness

Affiliations

Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness

Juan Morote et al. Int J Mol Sci. .

Abstract

The aim of this study was to analyze the relationship between statin use along with serum cholesterol levels and prostate cancer (PCa) detection and aggressiveness. Statin users of three years or more and serum cholesterol levels (SC) were assessed in 2408 men scheduled for prostate biopsy. SC was classified as normal (NSC: <200 mg/dL) or high (HSC: >200 mg/dL). High-grade PCa (HGPCa) was considered if the Gleason score was greater than 7. Statin users comprised 30.9% of those studied. The PCa detection rate was 31.2% of men on statins and 37% of non-statin users (p<0.006). The PCa detection rate was 26.3% in men with NSC and 40.6% in those with HSC (p<0.001). In the subset of NSC men, the PCa rate was 26.5% for statin users and 26.2% for non-users (p=0.939), while in men with HSC, the PCa rate was 36.4% for statin users and 42.0% for non-statin users (p=0.063). The HGPCa rate was 41.8% for statin users and 32.5% for non-users (p=0.012). NSC men had a 53.8% rate of HGPCa, while the rate was only 27.6% in HSC men (p<0.001). NSC men on statins had an HGPCa rate of 70.2%, while non-statin users had a rate of 41.2% (p<0.001). The HGPCa rate for HSC men on statins was 18.8%, while the rate was 30.0% (p=0.011) for non-users. Logistic regression analysis suggested that serum cholesterol levels could serve as an independent predictor of PCa risk, OR 1.87 (95% CI 1.56-2.24) and HGPCa risk, OR 0.31 (95% CI 0.23-0.44), while statin usage could not. Statin treatment may prevent PCa detection through serum cholesterol-mediated mechanisms. A disturbing increase in the HGPCa rate was observed in statin users who normalized their serum cholesterol.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Risk of prostate cancer (PCa) detection and high-grade PCa detection according to the quality of serum cholesterol level and chronic statin use. PB, prostatic biopsy; *, p < 0.0001, OR: 1.917 (95% Cl 1.601–2.295); **, p < 0.001, OR: 0.329 (95% Cl 0.241–0.448); , p = 0.939, OR: 1.020 (95% Cl 0.757–1.373); ††, p < 0.001, OR: 3.263 (95% Cl 1.975–5.781); , p = 0.063, OR: 0.790 (95% Cl 0.618–1.012); ∫∫, p < 0.011, OR: 0.538 (95% Cl 0.332–0.874).

Similar articles

Cited by

References

    1. Jemal A., Bray F., Center M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011;61:69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. Bay F., Lortet-Tieulent J., Ferlay J., Forman D., Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: An overview. Eur. J. Cancer. 2010;46:3040–3052. doi: 10.1016/j.ejca.2010.09.013. - DOI - PubMed
    1. Anand S.S., Yusuf S. Stemming the global tsunami of cardiovascular disease. Lancet. 2011;377:529–532. doi: 10.1016/S0140-6736(10)62346-X. - DOI - PubMed
    1. Gutt R., Tonlaar N., Kunnavakkam R., Karrison T., Weichselbaum R., Liauw S. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J. Clin. Oncol. 2010;28:2653–2659. doi: 10.1200/JCO.2009.27.3003. - DOI - PubMed
    1. Gonyeau M., Yuen D. A clinical review of statins and cancer: Helpful or harmful? Pharmacotherapy. 2010;30:177–194. doi: 10.1592/phco.30.2.177. - DOI - PubMed

Publication types

Substances